Bruker Co. (NASDAQ:BRKR) Given Consensus Recommendation of "Moderate Buy" by Analysts

Shares of Bruker Co. (NASDAQ:BRKR - Get Free Report) have been given a consensus rating of "Moderate Buy" by the eleven analysts that are presently covering the stock, Marketbeat Ratings reports. Five investment analysts have rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $65.00.

Several brokerages have weighed in on BRKR. Citigroup lowered their price target on Bruker from $75.00 to $50.00 and set a "buy" rating for the company in a report on Monday, April 7th. Stifel Nicolaus dropped their target price on shares of Bruker from $70.00 to $57.00 and set a "hold" rating on the stock in a research report on Friday, February 14th. Wells Fargo & Company decreased their price target on shares of Bruker from $75.00 to $60.00 and set an "overweight" rating for the company in a report on Thursday, April 17th. Barclays dropped their price objective on shares of Bruker from $60.00 to $50.00 and set an "overweight" rating on the stock in a report on Thursday, April 10th. Finally, Guggenheim restated a "buy" rating on shares of Bruker in a research note on Monday, February 24th.

Institutional Investors Weigh In On Bruker

Hedge funds have recently bought and sold shares of the stock. Barclays PLC boosted its holdings in Bruker by 36.5% during the third quarter. Barclays PLC now owns 55,685 shares of the medical research company's stock worth $3,847,000 after buying an additional 14,888 shares in the last quarter. Retirement Systems of Alabama boosted its stake in shares of Bruker by 11.7% during the 3rd quarter. Retirement Systems of Alabama now owns 134,254 shares of the medical research company's stock worth $9,272,000 after acquiring an additional 14,069 shares in the last quarter. GAMMA Investing LLC grew its position in shares of Bruker by 47.5% during the 4th quarter. GAMMA Investing LLC now owns 1,279 shares of the medical research company's stock valued at $75,000 after acquiring an additional 412 shares during the period. Everence Capital Management Inc. purchased a new position in shares of Bruker in the 4th quarter valued at about $251,000. Finally, Wealth Enhancement Advisory Services LLC boosted its position in Bruker by 1.4% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 13,287 shares of the medical research company's stock worth $779,000 after purchasing an additional 177 shares in the last quarter. Hedge funds and other institutional investors own 79.52% of the company's stock.

Bruker Stock Up 2.8 %

Bruker stock traded up $1.09 during trading hours on Friday, reaching $40.44. The stock had a trading volume of 3,505,606 shares, compared to its average volume of 1,526,469. The company has a market cap of $6.13 billion, a price-to-earnings ratio of 53.21, a PEG ratio of 2.16 and a beta of 1.23. The business's 50 day moving average price is $42.05 and its 200-day moving average price is $51.83. Bruker has a 52 week low of $34.10 and a 52 week high of $79.78. The company has a debt-to-equity ratio of 1.15, a current ratio of 1.60 and a quick ratio of 0.77.

Bruker (NASDAQ:BRKR - Get Free Report) last posted its earnings results on Thursday, February 13th. The medical research company reported $0.76 EPS for the quarter, beating analysts' consensus estimates of $0.75 by $0.01. Bruker had a net margin of 3.36% and a return on equity of 21.01%. Sell-side analysts anticipate that Bruker will post 2.69 EPS for the current year.

Bruker Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, March 28th. Investors of record on Monday, March 17th were issued a dividend of $0.05 per share. This represents a $0.20 annualized dividend and a yield of 0.49%. The ex-dividend date was Monday, March 17th. Bruker's dividend payout ratio (DPR) is 26.32%.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.